We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The nice thing about etripamil is that it is designed for at-home use. When patients cannot terminate PSVT, the next step is to go into the ER for an intravenous dose of the medication. And when they get their drugs, some patients can have chest discomfort, shortness of breath, or tiredness; the feeling that their heart stops and pauses for a long period of time. The nice thing about etripamil is that it's a bit gentler, there are no pauses.”
“Currently, no medications are approved for acute termination of paroxysmal supraventricular tachycardia without direct medical supervision. The unpredictable nature of PSVT places an overwhelming burden on patients who lack effective at-home interventions to manage their episodes.”
“Having an option to self-treat PSVT that is safe and effective would certainly help patients and expands their treatment options from what is currently available, [namely] catheter ablation versus maintenance/daily therapy—which may have some side effects—or pill-in-the-pocket treatment, which has not been shown to be safe and effective and is associated with possible hypotension and syncope.”
No takes yet. Share an insight, caveat, or question.
Ip et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: